908 Devices (NASDAQ:MASS) Receives "Sell (D-)" Rating from Weiss Ratings

908 Devices (NASDAQ:MASS - Get Free Report)'s stock had its "sell (d-)" rating reissued by stock analysts at Weiss Ratings in a report issued on Saturday,Weiss Ratings reports.

Separately, Stephens reissued an "overweight" rating and issued a $6.00 target price on shares of 908 Devices in a research report on Wednesday, January 15th. Two analysts have rated the stock with a hold rating and two have assigned a buy rating to the stock. According to MarketBeat.com, the stock currently has a consensus rating of "Moderate Buy" and an average target price of $5.33.

908 Devices Price Performance

908 Devices stock traded up $0.11 during mid-day trading on Friday, reaching $5.73. 459,312 shares of the company traded hands, compared to its average volume of 985,103. 908 Devices has a 52-week low of $1.81 and a 52-week high of $7.48. The firm has a market capitalization of $204.79 million, a price-to-earnings ratio of -3.24 and a beta of 0.26. The firm's 50 day moving average price is $4.48 and its 200 day moving average price is $3.24.

Institutional Inflows and Outflows

A number of large investors have recently bought and sold shares of the business. Geode Capital Management LLC increased its stake in shares of 908 Devices by 2.4% during the fourth quarter. Geode Capital Management LLC now owns 581,300 shares of the company's stock valued at $1,279,000 after purchasing an additional 13,512 shares in the last quarter. Barclays PLC increased its position in 908 Devices by 452.7% during the 3rd quarter. Barclays PLC now owns 46,214 shares of the company's stock valued at $160,000 after buying an additional 37,853 shares in the last quarter. Concurrent Investment Advisors LLC bought a new position in 908 Devices during the 4th quarter valued at approximately $52,000. Prudential Financial Inc. purchased a new position in 908 Devices during the fourth quarter valued at $34,000. Finally, LPL Financial LLC boosted its holdings in 908 Devices by 13.0% in the fourth quarter. LPL Financial LLC now owns 63,287 shares of the company's stock worth $139,000 after acquiring an additional 7,295 shares in the last quarter. 88.06% of the stock is owned by hedge funds and other institutional investors.

908 Devices Company Profile

908 Devices Inc, a commercial-stage technology company, provides various purpose-built handheld and desktop mass spectrometry devices to interrogate unknown and invisible materials in life sciences research, bioprocessing, pharma/biopharma, forensics, and adjacent markets. The company's products include MX908, a handheld, battery-powered, and Mass Spec device that is designed for rapid analysis of solid, liquid, vapor, and aerosol materials of unknown identity; Rebel, a small desktop analyzer that provides real-time information on the extracellular environment in bioprocesses; and Maverick, an optical in-line analyzer that offers real-time monitoring and control of multiple bioprocess parameters, including glucose, lactate, and total biomass in mammalian cell cultures, as well as provides process fingerprint data to support large-scale efforts in predictive bioprocess modeling.